In 2021 the European Haemophilia Consortium (EHC) received funding from the sources below. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.
The full accounts can be consulted in the EHC 2021 Annual Report.
EHC Funding 2021 - Industry versus non-industry funding
Source of income | Amount in € | % of the total income |
Non-industry | 288,643.29 | 13% |
Industry | 1,850,000 | 87% |
Highest industry contribution | 285,000 | 13% |
EHC non-industry funding - 2021
Funding source | Amount in € | % of the total income |
EHC membership | 11,150 | 0.5% |
Volunteer (non-remunerated) contributions | 267,000 | 12% |
Other sources of support | 1,840.45 | 0.08% |
Other operating income | 1,137.96 | 0.05% |
EHC Conference surplus | 7,514.88 | 0.3% |
Subtotal | 288,643.29 | 13% |
EHC industry-related funding - 2021
Funding source | Amount in € | % of total income |
Bayer | 105,000 | 4.9% |
BioMarin | 237,000 | 11.1% |
Biotest | 10,000 | 0.46% |
CSL Behring | 85,000 | 3.9% |
Freeline | 5,000 | 0.23% |
Kedrion | 15,000 | 0.23% |
LFB | 10,000 | 0.46% |
Novo Nordisk | 95,000 | 4,4% |
Pfizer | 90,000 | 4.2% |
Roche | 285,000 | 13,3% |
Sanofi | 275,000 | 12.8% |
Sigilon | 5,000 | 0.23% |
Sobi | 265,000 | 12.4% |
Spark | 130,000 | 6% |
Takeda | 235,000 | 10.9% |
UniQure | 3,000 | 0.14% |
Vifor | 10,000 | 0.46% |
Subtotal | 1,850,000 | 87% |